Published Technical Disclosure Archive

Expanding SYNP161 Technology to New Therapeutic Applications

Publication ID: 24-11857642_0007_PTD
Published: October 28, 2025
Category:New Applications & Use Cases

Legal Citation

pr1or.art Inc., “Expanding SYNP161 Technology to New Therapeutic Applications,” Published Technical Disclosure No. 24-11857642_0007_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857642_0007_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,642.

Summary of the Inventive Concept

The inventive concept disclosed herein leverages the core technology of SYNP161, a promoter for the expression of genes, to unlock new therapeutic possibilities in diverse fields, including dermatology, musculoskeletal health, respiratory medicine, oncology, and neuroscience.

Background and Problem Solved

The original SYNP161 patent focused on gene expression in rod photoreceptor cells. However, the limitations of this technology lie in its restricted applicability to a specific cell type. The inventive concept addresses this limitation by exploring the potential of SYNP161 in entirely new industries and problem spaces, thereby expanding its therapeutic reach and value.

Detailed Description of the Inventive Concept

The inventive concept involves applying the SYNP161 promoter technology to novel therapeutic applications, including treating skin conditions, enhancing muscle growth, combating respiratory diseases, detecting cancer, and improving cognitive function. This is achieved by combining the SYNP161 promoter with nucleic acid sequences encoding for specific genes, tailored to each target cell type or disease. The resulting expression cassettes, vectors, and compositions enable targeted gene expression, leading to innovative therapeutic solutions.

Novelty and Inventive Step

The inventive concept's novelty lies in its application of SYNP161 technology to entirely new fields and use cases, thereby expanding its therapeutic scope. The inventive step resides in the recognition of SYNP161's potential beyond its original application and the development of novel combinations and formulations that unlock its value in diverse therapeutic areas.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could involve the use of different promoter sequences, gene combinations, or vector systems to achieve targeted gene expression. Variations could also include the application of SYNP161 technology to additional therapeutic areas, such as cardiology or immunology, or the development of novel delivery methods for the expression cassettes and vectors.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in various industries, including pharmaceuticals, biotechnology, and medical devices. The target markets include dermatology, musculoskeletal health, respiratory medicine, oncology, and neuroscience, with potential applications in both human and veterinary medicine.

CPC Classifications

SectionClassGroup
A A61 A61K48/0058
A A61 A61K48/00
C C12 C12N15/63
C C12 C12N15/79
C C12 C12N15/86
C C12 C12N2750/14143
C C12 C12N2830/008

Field of Art

Molecular biology and gene therapy, specifically focused on targeted gene expression using promoter sequences, with expertise in genetic engineering, vector design, and cell-specific gene delivery techniques

Person of Ordinary Skill (PHOSITA) Profile

A molecular biologist with advanced training in genetic engineering, experienced in designing expression cassettes, understanding promoter functionality, and creating targeted gene delivery systems across multiple cell types

Obviousness Rationale

A PHOSITA would recognize that the SYNP161 promoter's core functionality of enabling cell-specific gene expression could be systematically extended to different cell types and therapeutic applications by simply substituting the target gene and selecting appropriate cell-specific targeting mechanisms. The source patent establishes the fundamental technology of a promoter sequence with high sequence identity that enables targeted gene expression, which inherently suggests potential adaptability across various biological contexts.

Obvious Combinations & Variations

Source Patent Element
Promoter sequence with at least 95% identity to SEQ ID NO:1 for rod photoreceptor cell gene expression
PTD Variation
Applying the same promoter sequence to keratinocyte, muscle, lung epithelial, and neuronal cell types
Obviousness Reasoning
Known technique of promoter sequence adaptation, predictable results in gene expression across related cell types, finite set of potential cell-specific applications
Source Patent Element
Expression cassette comprising nucleic acid sequence and gene encoding element
PTD Variation
Expanding therapeutic applications from initial rod photoreceptor focus to skin conditions, muscle growth, respiratory diseases, cancer detection, and cognitive function
Obviousness Reasoning
Predictable extension of gene therapy principles, using established molecular biology techniques to target different cellular processes
Source Patent Element
Viral vector delivery mechanism
PTD Variation
Applying viral vector delivery to diverse therapeutic contexts beyond original photoreceptor targeting
Obviousness Reasoning
Well-established gene delivery technique, known interchangeability of viral vectors across different cellular targets
Source Patent Element
Minimal promoter configuration
PTD Variation
Adapting minimal promoter design to create cell-type specific expression cassettes
Obviousness Reasoning
Standard molecular biology design approach, finite set of predictable modifications to achieve targeted gene expression
Source Patent Element
Gene expression method involving transfection
PTD Variation
Extending transfection methodology to multiple therapeutic and diagnostic contexts
Obviousness Reasoning
Routine application of established genetic engineering techniques, predictable results in gene delivery across different cellular environments
35 U.S.C. § 103 Summary: Pursuant to 35 U.S.C. ยง 103, the variations disclosed in the instant publication would have been obvious to a person having ordinary skill in the art at the time of invention, as they represent predictable extensions of the foundational gene expression technology disclosed in US Patent 11857642, involving routine molecular biology techniques and foreseeable adaptations of a known promoter sequence to alternative cellular contexts and therapeutic applications.

Original Patent Information

Patent NumberUS 11,857,642
TitleSYNP161, a promoter for the expression of genes
Assignee(s)FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH